Tuesday, January 30, 2024 12:55:35 PM
Recent NEXI News
- Konzernergebnis zum 31. Dezember 2023 genehmigt, starke Margenausweitung und Liquiditätsüberschuss von 601 Millionen Euro, Aktienrückkaufprogramm von 500 Millionen Euro • Business Wire • 03/07/2024 06:20:00 PM
- Approbation des résultats financiers du groupe au 31 décembre 2023 ; forte expansion de la marge et génération d'excédents de trésorerie à hauteur de 601 millions d’euros ; programme de rachat d’actions de 500 millions d’euros • Business Wire • 03/07/2024 05:33:00 PM
- Approvati i risultati finanziari di Gruppo al 31 dicembre 2023, Forte espansione dell’EBITDA margin ed excess cash generation a € 601 milioni, € 500 milioni per acquisto di azioni proprie • Business Wire • 03/07/2024 06:31:00 AM
- Group Financial Results as of December 31st 2023 Approved, Strong Margin Expansion and Excess Cash Generation at € 601 Million, € 500 Million Share Buy-Back Program • Business Wire • 03/07/2024 06:30:00 AM
- NexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 02/06/2024 09:42:41 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 02/06/2024 09:30:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2024 10:10:04 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/05/2024 09:34:15 PM
- NexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 02/02/2024 07:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 06:25:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 02:17:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:43:51 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 01/18/2024 09:43:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 09:01:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/01/2023 06:39:59 PM
- Form 144/A - Report of proposed sale of securities: [Amend] • Edgar (US Regulatory) • 11/22/2023 10:40:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:18:01 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/21/2023 09:39:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/20/2023 10:19:01 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/20/2023 10:01:30 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/17/2023 09:03:42 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 09:17:28 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/09/2023 10:47:49 PM
- Finanzergebnisse der Gruppe zum 30. September 2023 bestätigen solide finanzielle Leistung im Rahmen des Plans und kontinuierliche Ausweitung der EBITDA-Marge • Business Wire • 11/09/2023 02:35:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM